Simon Hitier
Papers
1
Total Citations
25
H-Index
1
About
Simon Hitier’s research focuses on the clinical development and real-world application of oncology therapies, particularly in advanced prostate cancer. His major contribution lies in the comprehensive analysis of cabazitaxel, a taxane chemotherapy, for patients with metastatic castration-resistant prostate cancer (mCRPC). Hitier co-authored a pivotal pooled analysis of the compassionate use and early access programmes, which evaluated cabazitaxel’s safety and efficacy in a large, diverse patient population outside of clinical trials. This work, cited 25 times, provided crucial evidence that cabazitaxel is a viable treatment option even in heavily pretreated patients, helping to bridge the gap between controlled studies and everyday clinical practice. By demonstrating consistent outcomes across different healthcare settings, Hitier’s analysis has informed treatment guidelines and supported broader access to this therapy. His research underscores the importance of real-world data in validating and refining cancer treatments, offering valuable insights for clinicians and researchers working to improve outcomes in mCRPC. Through this work, Hitier has contributed to a more nuanced understanding of how to manage this challenging disease.
Research Focus
Key Achievements
Top Papers
- 1